At a glance
A p53-derived experimental construct investigated in cancer-cell models.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Cell and animal oncology findings do not establish a human cancer treatment. The source’s proposed schedules should not be read as clinical protocols.[2][6][7]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of PNC-27.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 30 mg · 1 source tables
Standard / Gradual Approach (3 mL = 10 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg (0.10 mg) | 1 unit (0.01 mL) |
| Weeks 3–4 | 200 mcg (0.20 mg) | 2 units (0.02 mL) |
| Weeks 5–8 | 300 mcg (0.30 mg) | 3 units (0.03 mL) |
| Weeks 9–12 | 400 mcg (0.40 mg) | 4 units (0.04 mL) |
| Weeks 13–16 | 500 mcg (0.50 mg) | 5 units (0.05 mL) |
Frequency: Inject once daily subcutaneously. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability. Critical Note: No authoritative human dosing exists for PNC-27. The FDA warns that PNC-27 safety has not been established[3]. Any dosing above a few hundred micrograms per day is purely speculative[4].
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Educational exploration of a p53‑derived peptide studied preclinically for selective cancer‑cell membrane disruption[1][2].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 100–500 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 30 mg vial (10 mg/mL) for simplified unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 100 mcg daily for 1–2 weeks; increase by ~100 mcg every 2 weeks as tolerated.
- Target: 300–500 mcg daily by Weeks 5–16.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality[5].
- Lyophilized: Store at −20 °C (−4 °F) or colder (−80 °C / −112 °F ideal) in dry, dark conditions; short‑term refrigeration at 2–8 °C (35.6–46.4 °F) is acceptable for days to weeks.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Materials & quantity planning
Source materials checklist · 30 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (PNC-27, 30 mg each):
- 8 weeks ≈ 1 vial (~15–20 mg total used)
- 12 weeks ≈ 1 vial (~25 mg total used)
- 16 weeks ≈ 2 vials (~35–40 mg total used)
-
Insulin Syringes (U‑100 or 30/50‑unit for precision):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- 12 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- 16 weeks (2 vials): 6 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 30 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
Cancer Chemotherapy and Pharmacology (2010) — PNC-27 induces tumor cell membrane lysis; preclinical mechanism study (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Source document
Peptide Sciences — Peptide storage guidelines: lyophilized and reconstituted stability (opens in a new tab)www.peptidesciences.com
Back to overview ↑ - 06
Source document
BMC Cancer (2008) — PNC-27 selectively kills cancer cells via HDM-2 binding and membrane disruption (opens in a new tab)bmccancer.biomedcentral.com
Back to overview ↑ - 07
Research publication
PubMed (2012) — PNC-27 peptide induces necrosis via direct membrane lysis mechanism (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 08
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site guidance) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 10
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑